UBS AM
VYGR icon

UBS AM’s Voyager Therapeutics VYGR Stock Holding History

UBS AM’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08K Hold
595
– – ﹤0.01% 3534
2026
Q1 		$2.3K Buy
+595
New +$2.34K ﹤0.01% 3571
2023
Q1 		– Sell
-48,900
Closed -$298K – 2720
2022
Q4 		$298K Buy
+48,900
New +$278K ﹤0.01% 2330
2021
Q2 		– Sell
-26,231
Closed -$124K – 2781
2021
Q1 		$124K Buy
26,231
+12,222
+87% +$83.3K ﹤0.01% 2586
2020
Q4 		$100K Hold
14,009
– – ﹤0.01% 2534
2020
Q3 		$149K Hold
14,009
– – ﹤0.01% 2438
2020
Q2 		$177K Hold
14,009
– – ﹤0.01% 2412
2020
Q1 		$128K Sell
14,009
-279,967
-95% -$3.21M ﹤0.01% 2368
2019
Q4 		$4.1M Sell
293,976
-18,945
-6% -$275K ﹤0.01% 1277
2019
Q3 		$5.39M Buy
312,921
+2,839
+0.9% +$59.6K ﹤0.01% 1178
2019
Q2 		$8.44M Buy
310,082
+10,688
+4% +$245K 0.01% 1008
2019
Q1 		$5.73M Sell
299,394
-13,505
-4% -$176K ﹤0.01% 1101
2018
Q4 		$2.94M Sell
312,899
-22,772
-7% -$292K ﹤0.01% 1279
2018
Q3 		$6.35M Buy
335,671
+7,841
+2% +$150K ﹤0.01% 1066
2018
Q2 		$6.41M Buy
327,830
+60,728
+23% +$1.2M ﹤0.01% 1066
2018
Q1 		$5.02M Sell
267,102
-1,053
-0.4% -$22.8K ﹤0.01% 1145
2017
Q4 		$4.45M Buy
+268,155
New +$4.6M ﹤0.01% 1159

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

UBS AM's VYGR Position: Q2 2026 in Review

UBS AM held its Voyager Therapeutics (VYGR) position steady in Q2 2026 at 595 shares worth $2.08K. The position accounts for ﹤0.01% of the portfolio, ranked #3534.

UBS AM first reported a position in VYGR in Q4 2017 and has held it in 17 quarters since. The position peaked at $8.44M in Q2 2019. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • UBS AM held 595 shares of Voyager Therapeutics worth $2.08K as of Q2 2026.
  • UBS AM left its Voyager Therapeutics share count unchanged in Q2 2026.
  • Voyager Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3534 holding.
  • UBS AM first reported a position in Voyager Therapeutics in Q4 2017 and has held it in 17 quarters since.
  • UBS AM's Voyager Therapeutics position peaked at $8.44M in Q2 2019.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.